Drug discovery software developer Optibrium has launched version 6.5 of StarDrop™ which provides a complete platform for the design, optimisation and data analysis of small molecules. The latest release introduces WhichP450, a new feature in StarDrop’s P450 metabolism module that predicts which human cytochrome P450 enzymes are the major metabolising isoforms for a novel compound. Understanding how a compound is metabolised enables identification and analysis of its potential metabolites and guides the design of molecules with a reduced risk of drug-drug interactions or variations in exposure across the patient population.
Also included in the latest version of StarDrop is novel R-group clipping functionality that quickly transforms chemical building blocks into their corresponding substituents for enumeration of virtual libraries and the exploration of new compound ideas. Associated data, such as inventory and cost for each building block, are linked with the enumerated compounds to facilitate ordering for synthesis of the best compounds.
The new features have been introduced in parallel with an enhanced data visualisation environment offering more chart types, additional formatting options and a streamlined user interface, enabling publication-quality graphics to be created in a few clicks. This is teamed with a new ‘dashboard’ capability, combining multiple interactive plots in a configurable project view, enabling scientists, team leaders and managers to track the progress of a project at a glance.
For further information about Optibrium and StarDrop visit www.optibrium.com
- Optibrium and University of Nottingham collaborate on innovative teaching programme
- Optibrium and Enamine collaboration extends access to StarDrop commercial compound database
- Optibrium joins eTRANSAFE data standardisation project
- Optibrium, Imperial College and DNDi collaborate on drug development for neglected diseases
- Optibrium and Lhasa Limited in research and product development collaboration
- Molecular design specialist Optibrium appoints Zastra Innovations as software distributor in India
- Optibrium and eMolecules collaborate on data integration for pharmaceutical chemistry research
Latest from Tom Mulligan
- SGS’s first malaria human challenge trial will take place in Belgium this month
- TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products
- Horizon Discovery extends CRISPR Screening Service to primary human T cells
- TrakCel and The Quick Life Science Group partner on supply chain IT solution for cell and gene therapies
- Almac Group extends personalised cancer vaccine production facilities
- Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation
- Phico Therapeutics appoints financial director and two non-executive directors
- Evonetix appoints Stephanie Brooking as Head of Product Management
- Bio-Rad publishes new findings on generation and characterisation of drug-target-complex-specific antibodies
- Expedeon licenses Lightning-Link rapid biotinylation technology to Cell Guidance Systems